Blog
GLP-1 News & Updates
FDA updates, drug pricing news, insurance coverage changes, and the latest clinical trial results for GLP-1 weight loss medications.
Landmark Study Reveals GLP-1 Drugs' Surprising Health Benefits Beyond Weight Loss
A massive new analysis of 123 studies finds GLP-1 medications reduce risks for heart disease, kidney problems, cognitive decline, and fractures—reshaping how doctors think about these drugs.
The DoseRetatrutide Delivers Record 2% A1C Drop and 16.8% Weight Loss in Diabetes Trial
Eli Lilly's triple-agonist retatrutide achieved up to 2% A1C reduction and 36.6 pounds of weight loss in its first Phase 3 diabetes trial, marking a potential new standard for type 2 diabetes treatment.
The DoseSemaglutide Patent Expires in India, Triggering Generic GLP-1 Price War
Novo Nordisk's semaglutide patent expired in India on March 20, unleashing a wave of generic versions that cost 77% less than branded Ozempic and reshaping global GLP-1 access.
The DoseMedicare Launches Historic GLP-1 Coverage Bridge in July 2026
Medicare's new GLP-1 Bridge starts July 2026, offering Wegovy and Zepbound for $50/month to eligible beneficiaries with obesity and comorbidities.
The DoseGenetics May Predict Your GLP-1 Drug Response, Landmark Study Shows
New 23andMe research identifies genetic variants that explain why some people lose 20% of their weight on GLP-1s while others see minimal results.
The DoseMedicare Expands GLP-1 Coverage to 3.4 Million Seniors Under New CMS Rule
New Medicare rule reinterprets GLP-1 coverage criteria, enabling 3.4 million beneficiaries to access weight loss medications through cardiovascular risk reduction pathway.
The DoseAI-Powered GLP-1 Telehealth Giant MEDVi Faces FDA Warnings and Lawsuits
MEDVi, profiled by NYT as an AI-powered $1.8B telehealth success story, faces FDA warnings, RICO lawsuits over compounded GLP-1s, and major data breach affecting 1.6M patients.
The DoseFDA Safety Data Reveals Distinct Risk Profiles Across Different GLP-1 Drugs
New analysis of 137,000 FDA adverse event reports shows each GLP-1 medication has unique safety patterns, with semaglutide linked to more psychiatric events and concerning findings for women.
The DoseFirst Generic GLP-1 Hits Market as Liraglutide Shortage Continues
Generic liraglutide becomes first GLP-1 with generic availability, offering hope for lower costs while brand shortage persists.
The DoseLilly's Retatrutide Delivers Record 28.7% Weight Loss in First Phase 3 Trial
Eli Lilly's triple-agonist retatrutide achieved 28.7% average weight loss (71.2 pounds) in its first successful Phase 3 trial, setting a new efficacy record for obesity medications.
The DoseFDA Approves Foundayo: Eli Lilly's GLP-1 Pill with No Food Restrictions
Eli Lilly's Foundayo becomes the second GLP-1 pill approved for weight loss, offering unique flexibility with no food or water restrictions and $149 starting price.
The DoseFDA Delays Orforglipron Decision to April Amid Priority Voucher Program Setbacks
The FDA pushed back Eli Lilly's highly anticipated oral GLP-1 pill decision by two weeks to April 10, marking the first major delays in the new priority review program.